Improving the outcome for children with cancer: Development of targeted new agents

CA Cancer Journal for Clinicians

Volumn 65, Issue 3, 2015, Pages 212-220

  Adamson, Peter C ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

acute lymphoblastic leukemia; Children's Oncology Group; pediatric oncology hematology; research infrastructure

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BCR ABL PROTEIN; BLINATUMOMAB; CD135 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA SECRETASE; IMATINIB; IMMUNOSUPPRESSIVE AGENT; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN INHIBITOR; PROTEIN KINASE B; SOMATOMEDIN C DERIVATIVE; SOMATOMEDIN C INHIBITOR; SOMATOMEDIN RECEPTOR; SONIC HEDGEHOG PROTEIN; TRANSCRIPTOME; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH INHIBITOR; VASCULOTROPIN; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE; BONE MARROW SUPPRESSION; CANADA; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RESEARCH; CHILDHOOD CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DEMOGRAPHY; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG RESEARCH; DRUG TARGETING; EPIGENOME; EUROPE; EVENT FREE SURVIVAL; EWING SARCOMA; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; GENOME; HEALTH CARE QUALITY; HUMAN; HYPERTENSION; INFECTION CONTROL; KIDNEY TUMOR; LEUKOCYTE COUNT; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; MOLECULAR UNDERPINNING; MORBIDITY; MORQUIO SYNDROME; MORTALITY; NEUROBLASTOMA; OPPORTUNISTIC INFECTION; OSTEOSARCOMA; OUTCOME ASSESSMENT; PEDIATRICS; PHENOTYPE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SURVIVAL TIME; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TRANSLATIONAL RESEARCH; TREATMENT DURATION; TREATMENT INDICATION; UNITED STATES; CHILD; DRUG CONTROL; DRUG DEVELOPMENT; MEDICINAL CHEMISTRY; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; CHILD; DRUG AND NARCOTIC CONTROL; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; TREATMENT OUTCOME; UNITED STATES;

EID: 84929133921     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21273     Document Type: Review

References (66)

1. Hunger SP, Loh ML, Whitlock JA, et al. Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013; 60: 957-963.
2. Hirschfeld S, Ho PT, Smith M, Pazdur R,. Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives. J Clin Oncol. 2003; 21: 1066-1073.
3. Freireich EJ, Kliman A, Gaydos LA, Mantel N, Frei E, 3rd. Response to repeated platelet transfusion from the same donor. Ann Intern Med. 1963; 59: 277-287.
4. Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1977; 297: 1419-1426.
5. Pizzo PA,. Infectious complications in the child with cancer. II. Management of specific infectious organisms. J Pediatr. 1981; 98: 513-523.
6. Pizzo PA,. Infectious complications in the child with cancer. I. Pathophysiology of the compromised host and the initial evaluation and management of the febrile cancer patient. J Pediatr. 1981; 98: 341-354.
7. Pizzo PA,. Infectious complications in the child with cancer. III. Prevention. J Pediatr. 1981; 98: 524-530.
8. Furman WL, Fairclough DL, Huhn RD, et al. Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy. J Clin Oncol. 1991; 9: 1022-1028.
9. Wexler LH, Weaver-McClure L, Steinberg SM, et al. Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy. J Clin Oncol. 1996; 14: 901-910.
10. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995; 13: 610-630.
11. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006; 355: 1572-1582.
12. Heyn RM, Brubaker CA, Burchenal JH, Cramblett HG, Wolff JA,. The comparison of 6-mercaptopurine with the combination of 6-mercaptopurine and azaserine in the treatment of acute leukemia in children: results of a cooperative study. Blood. 1960; 15: 350-359.
13. O'Leary M, Krailo M, Anderson JR, Reaman GH,. Progress in childhood cancer: 50 years of research collaboration, a report from the Children's Oncology Group. Semin Oncol. 2008; 35: 484-493.
14. Nass SJ, Moses HL, Mendelsohn J, eds; Committee on Cancer Clinical Trials and the NCI Cooperative Group Program; Institute of Medicine. A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. Washington, DC: The National Academies Press; 2010.
15. Murthy VH, Krumholz HM, Gross CP,. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004; 291: 2720-2726.
16. Sateren WB, Trimble EL, Abrams J, et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol. 2002; 20: 2109-2117.
17. Kohn LT, Corrigan JM, Donaldson MS, eds. To Err Is Human: Building a Safer Health System. Washington, DC: The National Academies Press; 2000.
18. Schroen AT, Petroni GR, Wang H, et al. Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from US Cooperative Oncology Groups. Clin Cancer Res. 2012; 18: 256-262.
19. Institute of Medicine. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. An American Society of Clinical Oncology and Institute of Medicine Workshop. Washington, DC: The National Academies Press; 2013.
20. Mendelsohn J, Bertagnolli MM,. The 2010 Institute of Medicine consensus statement "A national clinical trials network for the 21st century": progress and challenges. Semin Oncol. 2014; 41: 435-436.
21. Freyer DR, Felgenhauer J, Perentesis J,; COG Adolescent and Young Adult Oncology Discipline Committee. Children's Oncology Group's 2013 blueprint for research: adolescent and young adult oncology. Pediatr Blood Cancer. 2013; 60: 1055-1058.
22. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344: 1031-1037.
23. Champagne MA, Capdeville R, Krailo M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood. 2004; 104: 2655-2660.
24. Champagne MA, Fu CH, Chang M, et al. Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011; 57: 56-62.
25. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol. 2009; 27: 5175-5181.
26. Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia. 2014; 28: 1467-1471.
27. Jakacki RI, Hamilton M, Gilbertson RJ, et al. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group phase I consortium study. J Clin Oncol. 2008; 26: 4921-4927.
28. Fouladi M, Stewart CF, Blaney SM, et al. Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J Clin Oncol. 2010; 28: 4221-4227.
29. Geoerger B, Hargrave D, Thomas F, et al. Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol. 2011; 13: 109-118.
30. Glade Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group study. J Clin Oncol. 2008; 26: 399-405.
31. Kieran MW, Supko JG, Wallace D, et al. Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. Pediatr Blood Cancer. 2009; 52: 169-176.
32. Fox E, Aplenc R, Bagatell R, et al. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol. 2010; 28: 5174-5181.
33. Mosse YP, Balis FM, Lim MS, et al. Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: a Children's Oncology Group phase I consortium study [abstract]. J Clin Oncol. 2012; 30 (suppl). Abstract 9500.
34. Bagatell R, Herzog CE, Trippett TM, et al. Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors. Clin Cancer Res. 2011; 17: 611-619.
35. Malempati S, Weigel B, Ingle AM, et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012; 30: 256-262.
36. Gajjar A, Stewart CF, Ellison DW, et al. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res. 2013; 19: 6305-6312.
37. Spunt SL, Grupp SA, Vik TA, et al. Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. J Clin Oncol. 2011; 29: 2933-2940.
38. Fouladi M, Perentesis JP, Phillips CL, et al. A phase I trial of MK-2206 in children with refractory malignancies: a Children's Oncology Group study. Pediatr Blood Cancer. 2014; 61: 1246-1251.
39. Fouladi M, Stewart CF, Olson J, et al. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Clin Oncol. 2011; 29: 3529-3534.
40. Kim A, Balis FM, Widemann BC,. Sorafenib and sunitinib. Oncologist. 2009; 14: 800-805.
41. Widemann BC, Kim A, Fox E, et al. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. Clin Cancer Res. 2012; 18: 6011-6022.
42. Gombos A, Metzger-Filho O, Dal Lago L, Awada-Hussein A,. Clinical development of insulin-like growth factor receptor-1 (IGF-1R) inhibitors: at the crossroad? Invest New Drugs. 2012; 30: 2433-2442.
43. Pappo AS, Vassal G, Crowley JJ, et al. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study. Cancer. 2014; 120: 2448-2456.
44. Schoffski P, Adkins D, Blay JY, et al. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. Eur J Cancer. 2013; 49: 3219-3228.
45. Wagner LM, Fouladi M, Ahmed A, et al. Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2015; 62: 440-444.
46. Olmos D, Postel-Vinay S, Molife LR, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol. 2010; 11: 129-135.
47. Dorsey ER, de Roulet J, Thompson JP, et al. Funding of US biomedical research, 2003-2008. JAMA. 2010; 303: 137-143.
48. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer. 2007; 49: 928-940.
49. Neale G, Su X, Morton CL, et al. Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res. 2008; 14: 4572-4583.
50. Office of Cancer Genomics, National Cancer Institute, National Institutes of Health. TARGET: Therapeutically Applicable Research to Generate Effective Treatments. ocg.cancer.gov/programs/target. Accessed January 3, 2015.
51. Mullighan CG, Zhang J, Harvey RC, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2009; 106: 9414-9418.
52. Harvey RC, Mullighan CG, Chen IM, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood. 2010; 115: 5312-5321.
53. Loh ML, Zhang J, Harvey RC, et al. Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. Blood. 2013; 121: 485-488.
54. Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014; 371: 1005-1015.
55. Roberts R, Rodriguez W, Murphy D, Crescenzi T,. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. JAMA. 2003; 290: 905-911.
56. Field MJ, Boat TF, eds. Safe and Effective Medicines for Children: Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. Washington, DC: The National Academies Press; 2012.
57. Olski TM, Lampus SF, Gherarducci G, Saint Raymond A,. Three years of paediatric regulation in the European Union. Eur J Clin Pharmacol. 2011; 67: 245-252.
58. Adamson PC,. Unintended consequences of regulatory initiatives in childhood cancer drug development. JAMA Pediatr. 2013; 167: 886-887.
59. Vassal G, Zwaan CM, Ashley D, et al. New drugs for children and adolescents with cancer: the need for novel development pathways. Lancet Oncol. 2013; 14: e117-e124.
60. 111th US Congress. Senate bill S.3697. A bill to amend the Federal Food, Drug, and Cosmetic Act to improve the priority review voucher incentive program relating to tropical and rare pediatric diseases. Washington, DC: US Congress; 2011.
61. Eidelson J, Sanofi and Regeneron Pay $67.5 Million to Fast-Track a Cholesterol Drug. businessweek.com/articles/2014-08-04/sanofi-regeneron-pay-67-dot-5-million-to-expedite-a-cholesterol-drug. Accessed January 3, 2015.
62. Schlegel P, Lang P, Zugmaier G, et al. Pediatric post-transplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica. 2014; 99: 1212-1219.
63. Topp MS, Gokbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015; 16: 57-66.
64. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368: 1509-1518.
65. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371: 1507-1517.
66. Porter DL, Levine BL, Kalos M, Bagg A, June CH,. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365: 725-733.